Home › Research › Biomarkers
Prognostic value of plasma glial fibrillary acidic protein in cognitively unimpaired older adults: Results from the A4 study
Ghanbarian E, Qian T, Khorsand B, Zheng L, Sajjadi SA, Grill JD, Rabin LA, Lipton RB, Sperling RA, Ezzati A. Alzheimer's & Dementia, 2025-11
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Introduction Plasma glial fibrillary acidic protein (GFAP), a marker of astrocytic activation, has been linked to Alzheimer's disease; however, its prognostic value in cognitively unimpaired (CU) individuals remains unclear. Methods We included 949 CU older adults from the A4 preclinical AD trial and its companion LEARN cohort. Baseline plasma GFAP was measured, and associations with cognitive decline (Preclinical Alzheimer's Cognitive Composite [PACC]), Clinical Dementia Rating (CDR) progression, and imaging biomarkers were assessed over 240 weeks. Results Baseline plasma GFAP was higher in females and in A4 (amyloid-positive) versus LEARN (amyloid-negative) participants. Cross-sectionally, elevated GFAP was associated with lower cognitive performance and greater amyloid burden. Longitudinally, higher GFAP predicted faster cognitive decline, increased risk of CDR progression, AD-related cortical atrophy, and amyloid conversion, with stronger effects in females. Discussion Plasma GFAP is a prognostic biomarker in CU older adults, predicting cognitive and biological changes, with stronger associations observed in females, highlighting a possible sex-specific vulnerability. Highlights Elevated plasma glial fibrillary acidic protein (GFAP) predicted faster cognitive decline measured by Preclinical Alzheimer's Cognitive Composite (PACC). GFAP was associated with increased risk of progression to mild cognitive impairment. GFAP predicted conversion to amyloid positivity in amyloid-negative subjects. Higher baseline GFAP was associated with cortical atrophy in Alzheimer's disease (AD) -signature areas. Associations of GFAP with cognition and AD biomarkers were stronger in females.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 949 participants. In 949 cognitively unimpaired older adults, higher baseline plasma GFAP predicted faster cognitive decline, increased risk of CDR progression, AD-related cortical atrophy, and amyloid conversion, with stronger effects in females. Its stated limit: No definitive proof that blood GFAP originates from reactive astrocytes in the brain; GFAP is not specific to AD; A4 participants lacked baseline GFAP measurements so longitudinal analyses may be biased toward LEARN characteristics; only baseline GFAP was analysed.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Ghanbarian, E., Qian, T., Khorsand, B., Zheng, L., Sajjadi, S. A., Grill, J. D., et al. (2025). Prognostic value of plasma glial fibrillary acidic protein in cognitively unimpaired older adults: Results from the A4 study. Alzheimer's & Dementia. https://doi.org/10.1002/alz.70948
Vancouver
Ghanbarian E, Qian T, Khorsand B, Zheng L, Sajjadi SA, Grill JD, et al. Prognostic value of plasma glial fibrillary acidic protein in cognitively unimpaired older adults: Results from the A4 study. Alzheimer's & Dementia. 2025. doi:10.1002/alz.70948. PMID: 41268784.
BibTeX
@article{ghanbarian2025-41268784,
author = {Ghanbarian, E. and Qian, T. and Khorsand, B. and Zheng, L. and Sajjadi, S. A. and Grill, J. D. and Rabin, L. A. and Lipton, R. B. and Sperling, R. A. and Ezzati, A.},
title = {{Prognostic value of plasma glial fibrillary acidic protein in cognitively unimpaired older adults: Results from the A4 study}},
journal = {Alzheimer's \& Dementia},
year = {2025},
doi = {10.1002/alz.70948},
pmid = {41268784},
url = {https://doi.org/10.1002/alz.70948}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 10 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Results Baseline plasma GFAP was higher in females and in A4 (amyloid-positive) versus LEARN (amyloid-negative) participants.
- Cross-sectionally, elevated GFAP was associated with lower cognitive performance and greater amyloid burden.
- Longitudinally, higher GFAP predicted faster cognitive decline, increased risk of CDR progression, AD-related cortical atrophy, and amyloid conversion, with stronger effects in females.
- GFAP was associated with increased risk of progression to mild cognitive impairment.
- Higher baseline GFAP was associated with cortical atrophy in Alzheimer's disease (AD) -signature areas.
Why it matters
In 949 cognitively unimpaired older adults, higher baseline plasma GFAP predicted faster cognitive decline, increased risk of CDR progression, AD-related cortical atrophy, and amyloid conversion, with stronger effects in females. This identifies GFAP as a prognostic biomarker in cognitively unimpaired older adults, but it does not show that measuring or targeting GFAP prevents or treats Alzheimer's disease.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designcohort
- Participants949
- Evidence strengthModerate
Limitations
No definitive proof that blood GFAP originates from reactive astrocytes in the brain; GFAP is not specific to AD; A4 participants lacked baseline GFAP measurements so longitudinal analyses may be biased toward LEARN characteristics; only baseline GFAP was analysed.
How this study scored 58/100
Published in a leading specialty journal, and it is a cohort study following people over time. Scored zero for effect reported and randomized / blinded because the record does not state it. We have no data on free to read, so that was left out: it earned 57 of the 98 points we could judge it on, which is 58 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 949 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 9 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 3.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 5.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 2 other studies in this library |
| Still being cited | 1 / 4 | Cited 9 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Ali Ezzati: h-index 37 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Massachusetts General Hospital: institution h-index 2,057 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 6 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41268784) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 57 / 98 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 57 of the 98 points we could judge it on is 58 out of 100. |
| Total | 58 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 16.
Later studies that cite this one
2 studies in the alzhub library list this one in their references.
Related studies in Biomarkers from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.